157 related articles for article (PubMed ID: 34644524)
1. Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS).
Kawashiri T; Kobayashi D; Uchida M; Hiromoto S; Inoue M; Ikeda H; Inoue M; Shimazoe T
J Pharm Pharm Sci; 2021; 24():499-508. PubMed ID: 34644524
[TBL] [Abstract][Full Text] [Related]
2. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
3. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
[TBL] [Abstract][Full Text] [Related]
4. [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].
Haase D; Hanf V; Schulz T
Med Klin (Munich); 2004 Sep; 99(9):506-17. PubMed ID: 15372180
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.
Ben-Yehuda D; Krichevsky S; Caspi O; Rund D; Polliack A; Abeliovich D; Zelig O; Yahalom V; Paltiel O; Or R; Peretz T; Ben-Neriah S; Yehuda O; Rachmilewitz EA
Blood; 1996 Dec; 88(11):4296-303. PubMed ID: 8943866
[TBL] [Abstract][Full Text] [Related]
6. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C
J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748
[TBL] [Abstract][Full Text] [Related]
7. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
8. [Therapy-induced leukemia -- an underestimated complication of antineoplastic chemotherapy?].
Dührsen U
Zentralbl Gynakol; 2005 Aug; 127(4):235-41. PubMed ID: 16037905
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
10. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.
Smith RE
Clin Breast Cancer; 2003 Oct; 4(4):273-9. PubMed ID: 14651772
[TBL] [Abstract][Full Text] [Related]
11. Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines.
Ando M; Narabayashi M; Watanabe T; Kamiya Y; Togitani K; Tanosaki R; Takenaka T; Tobinai K; Adachi I
Jpn J Clin Oncol; 1999 Jan; 29(1):28-32. PubMed ID: 10073148
[TBL] [Abstract][Full Text] [Related]
12. [Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer].
Abe A; Ikawa H; Muguruma H; Maeda Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1795-8. PubMed ID: 18931592
[TBL] [Abstract][Full Text] [Related]
13. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
Kushner BH; Heller G; Cheung NK; Wollner N; Kramer K; Bajorin D; Polyak T; Meyers PA
J Clin Oncol; 1998 Sep; 16(9):3016-20. PubMed ID: 9738570
[TBL] [Abstract][Full Text] [Related]
14. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.
Smith MA; Rubinstein L; Anderson JR; Arthur D; Catalano PJ; Freidlin B; Heyn R; Khayat A; Krailo M; Land VJ; Miser J; Shuster J; Vena D
J Clin Oncol; 1999 Feb; 17(2):569-77. PubMed ID: 10080601
[TBL] [Abstract][Full Text] [Related]
15. [Acute myelogenous leukemia and myelodysplastic syndrome after treatment with cytostatic agents].
Abrahamsen AF
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2542-5. PubMed ID: 11070993
[TBL] [Abstract][Full Text] [Related]
16. Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer.
Colon-Otero G; Malkasian GD; Edmonson JH
J Natl Cancer Inst; 1993 Nov; 85(22):1858-60. PubMed ID: 8230267
[No Abstract] [Full Text] [Related]
17. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.
Leonard DG; Travis LB; Addya K; Dores GM; Holowaty EJ; Bergfeldt K; Malkin D; Kohler BA; Lynch CF; Wiklund T; Stovall M; Hall P; Pukkala E; Slater DJ; Felix CA
Clin Cancer Res; 2002 May; 8(5):973-85. PubMed ID: 12006509
[TBL] [Abstract][Full Text] [Related]
18. Secondary myelodysplastic syndromes and leukemias.
Giles FJ; Koeffler HP
Curr Opin Hematol; 1994 Jul; 1(4):256-60. PubMed ID: 9371291
[TBL] [Abstract][Full Text] [Related]
19. [Caution against secondary cancer induced by antitumor chemotherapy].
Ding X
Zhonghua Nei Ke Za Zhi; 1996 Sep; 35(9):579-80. PubMed ID: 9592347
[No Abstract] [Full Text] [Related]
20. [Therapy-related acute leukaemia and myelodysplastic syndrome].
Díaz Beveridge R; Aparicio Urtasun J
An Med Interna; 2003 May; 20(5):257-68. PubMed ID: 12831302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
